| The ROQ domain of Roquin recognizes mRNA constitutive-decay element and double-stranded RNA D Tan, M Zhou, M Kiledjian, L Tong Nature structural & molecular biology 21 (8), 679-685, 2014 | 91 | 2014 |
| Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience TL Rose, WH Weir, GM Mayhew, Y Shibata, P Eulitt, JM Uronis, M Zhou, ... British journal of cancer 125 (9), 1251-1260, 2021 | 89 | 2021 |
| Entinostat induces antitumor immune responses through immune editing of tumor neoantigens AS Truong, M Zhou, B Krishnan, T Utsumi, U Manocha, KG Stewart, ... The Journal of Clinical Investigation 131 (16), 2021 | 55 | 2021 |
| Mutations in DCPS and EDC3 in autosomal recessive intellectual disability indicate a crucial role for mRNA decapping in neurodevelopment I Ahmed, R Buchert, M Zhou, X Jiao, K Mittal, TI Sheikh, U Scheller, ... Human molecular genetics 24 (11), 3172-3180, 2015 | 52 | 2015 |
| Pparg signaling controls bladder cancer subtype and immune exclusion T Tate, T Xiang, SE Wobker, M Zhou, X Chen, H Kim, E Batourina, CS Lin, ... Nature communications 12 (1), 6160, 2021 | 42 | 2021 |
| Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3΄ variants D Yamane, SR Selitsky, T Shimakami, Y Li, M Zhou, M Honda, ... Nucleic Acids Research 45 (8), 4743-4755, 2017 | 31 | 2017 |
| Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity B Mirlekar, Y Wang, S Li, M Zhou, S Entwistle, T De Buysscher, ... Cell Reports Medicine 3 (9), 2022 | 29 | 2022 |
| DcpS is a transcript-specific modulator of RNA in mammalian cells M Zhou, S Bail, HL Plasterer, J Rusche, M Kiledjian Rna 21 (7), 1306-1312, 2015 | 23 | 2015 |
| RNA expression profiling of lymphoepithelioma-like carcinoma of the bladder reveals a basal-like molecular subtype U Manocha, J Kardos, S Selitsky, M Zhou, SM Johnson, C Breslauer, ... The American Journal of Pathology 190 (1), 134-144, 2020 | 16 | 2020 |
| Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer JS Damrauer, W Beckabir, J Klomp, M Zhou, ER Plimack, MD Galsky, ... Nature communications 13 (1), 6658, 2022 | 15 | 2022 |
| PBRM1 inactivation promotes upregulation of human endogenous retroviruses in a HIF-dependent manner M Zhou, JY Leung, KH Gessner, AJ Hepperla, JM Simon, IJ Davis, ... Cancer immunology research 10 (3), 285-290, 2022 | 15 | 2022 |
| Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy M Kiledjian, M Zhou US Patent App. 15/506,917, 2017 | 9 | 2017 |
| Normal and aberrantly capped mRNA decapping M Kiledjian, M Zhou, X Jiao The Enzymes 31, 165-180, 2012 | 6 | 2012 |
| FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression A Okato, T Utsumi, M Ranieri, X Zheng, M Zhou, LD Pereira, T Chen, ... The Journal of Clinical Investigation 134 (2), 2024 | 5 | 2024 |
| Viewing RCC with a DNA methylation lens ENHANCES understanding of ICI resistance M Zhou, WY Kim Clinical Cancer Research 29 (7), 1170-1172, 2023 | 1 | 2023 |
| Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience TL Rose, WH Weir, GM Mayhew, Y Shibata, P Eulitt, JM Uronis, M Zhou, ... British Journal of Cancer 126 (8), 1237, 2022 | 1 | 2022 |
| Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience (vol 125, pg 1251, 2021) TL Rose, WH Weir, GM Mayhew, Y Shibata, P Eulitt, JM Uronis, M Zhou, ... BRITISH JOURNAL OF CANCER 126 (8), 1237-1237, 2022 | 1 | 2022 |
| Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer W Beckabir, M Zhou, JS Lee, SP Vensko, MG Woodcock, HH Wang, ... Nature Communications 15 (1), 4448, 2024 | | 2024 |
| Abstract A016: NRF2 activation promotes a fitness disadvantage in normal urothelium and drives a basal-like phenotype A Hamada, Y Kita, D Wu, M Zhou, S Clark-Garvey, A Gdowski, ... Clinical Cancer Research 30 (10_Supplement), A016-A016, 2024 | | 2024 |
| Abstract B014: FGFR inhibition upregulates Nectin-4 expression in FGFR3 altered urothelial carcinoma S Clark-Garvey, M Zhou, M Sturdivant, W Beckabir, L Kim, ED Toomer, ... Clinical Cancer Research 30 (10_Supplement), B014-B014, 2024 | | 2024 |
